anti-CCR2 monoclonal anitbodies (Sorrento Therapeutics)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-CCR2 monoclonal anitbodies (Sorrento Therapeutics)
Drug Alias Nameanti-CCR2 mAbs (Sorrento Therapeutics)STI-B0201STI-B020X
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionC-C chemokine receptor type 2 antagonists
TargetsC-C chemokine receptor type 2
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSorrento Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSorrento Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsInflammation

Other Information

ATC CodeN/A
Related LinksN/A